True Freedom Investing LLC Buys New Shares in IQVIA Holdings Inc. $IQV

True Freedom Investing LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 22,297 shares of the medical research company’s stock, valued at approximately $3,803,000.

Several other large investors have also recently bought and sold shares of IQV. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth approximately $27,000. Compass Financial Management LLC bought a new stake in shares of IQVIA during the 2nd quarter worth approximately $27,000. Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $27,000. CrossGen Wealth LLC bought a new position in shares of IQVIA in the fourth quarter valued at $28,000. Finally, Activest Wealth Management increased its holdings in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after buying an additional 118 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on IQV shares. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research note on Thursday, July 9th. Royal Bank Of Canada boosted their price objective on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Stifel Nicolaus upped their target price on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Mizuho raised their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Robert W. Baird lifted their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

Insider Activity at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 12,913 shares of company stock worth $3,098,793 in the last quarter. Corporate insiders own 1.70% of the company’s stock.

IQVIA Trading Up 1.6%

Shares of IQVIA stock opened at $260.17 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The business has a fifty day simple moving average of $213.32 and a two-hundred day simple moving average of $187.52. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $260.40. The company has a market capitalization of $42.82 billion, a price-to-earnings ratio of 32.28, a P/E/G ratio of 2.21 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has initiated a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.